INVO 8-K filed 2026 · insiderdelta

Item
4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

The
previously issued unaudited consolidated financial statements of INVO Fertility, Inc. (the “Company”) as of March 31,
2025, June 30, 2025, and September 30, 2025 and the respective periods then ended (collectively, the “ Affected
Periods ”) are being restated as a result of an internal review. The errors identified during the internal review were
primarily related to highly technical derivative and debt extinguishment accounting as described in more detail below. The errors
did not impact the Company’s revenue or loss from operations and have not resulted in any change to the Company’s
business plan or operations. The impact of the errors are limited to the Company’s assets, liabilities, equity, other
income (expense), and net income (loss).

The Company
has identified the following errors in the Affected Periods: (i) incorrect classification of Series C-1 Preferred Stock, which should
have been classified as mezzanine equity in the first quarter of 2025; (ii) incorrect classification of Series C-2 Preferred Stock, which
should have been classified as mezzanine equity in the second quarter of 2025; (iii) incorrect treatment of a convertible debenture containing
an embedded derivative which should have been bifurcated; (iv) the incorrect recognition of a gain on settlement and corresponding reduction
to liabilities in connection with a binding term sheet entered into during the second quarter of 2025; (v) the incorrect equity classification
of common stock purchase warrants issued pursuant to a warrant inducement transaction during the second quarter of 2025, which should
have been classified as a liability; and (vi) the incorrect accounting treatment of an amendment to a promissory note entered into during
the third quarter of 2025, which should have been accounted for as a debt extinguishment under Accounting Standards Codification 470-50
(collectively, the “ 2025 Financial Statement Errors ”).

On June
1, 2026, the audit committee of the Company, after considering the recommendations of management, concluded that the Company’s
previously issued unaudited consolidated financial statements contained within its (i) Quarterly Report on Form 10-Q as of March 31,
2025 and for the three months then ended, filed with the Securities and Exchange Commission (“SEC”) on May 20, 2025,
(ii) Quarterly Report on Form 10-Q as of June 30, 2025 and for the three and six months then ended, filed with the SEC on August 14,
2025, and (iii) Quarterly Report on Form 10-Q as of September 30, 2025 and for the three and nine months then ended, filed with the SEC on November 17, 2025 should no longer be relied due the 2025 Financial Statement Errors.

The Company
intends to present the restatement of the affected line items of the unaudited consolidated financial statements for the Affected Periods
within the Company’s forthcoming Annual Report on Form 10-K for the year ended December 31, 2025. Under this approach, the previously
issued Quarterly Reports on Form 10-Q for the Affected Periods will not be amended; however, historical amounts presented in future Form
10-Q filings will be recast to be consistent.

The
Company’s management and audit committee have discussed the matters described herein
with the Company’s independent registered public accounting firm, WithumSmith+Brown, PC.
INVO Invo Bioscience, Inc. - 8-K

Item 4.02 - Non-Reliance on Previously Issued Financial Statements

Item 9.01 - Financial Statements and Exhibits
